International Journal of
Technology and Systems
(IJTS)

Harnessing the Power of Artificial Intelligence in Clinical Trials and Disease Modeling: Challenges and Future Directions

Journal of Technology and Systems
ISSN : 2788-6344 (Online)
Vol. 7, Issue No. 3, pp 12 – 22, 2025
www.carijournals.org

Harnessing the Power of Artificial Intelligence in Clinical Trials and Disease Modeling: Challenges and Future Directions

[1*] **Isham Kalappurackal Mansoor** [2] **Mansoor Veliyathnadu Ebrahim**

[1*] Student, Virginia Polytechnic Institute and State University, USA

[2] Solution Architect, Leading Health Insurance Company, USA

Crossref

Accepted: 20th Mar, 2025, Received in Revised Form: 4th Apr, 2025, Published: 18th Apr, 2025

Abstract

Purpose: This article explores the potential of artificial intelligence (AI) to transform clinical trials and disease modeling, focusing on how AI can enhance healthcare efficiency, precision, and personalization.

Methodology: The study involves reviewing existing literature and conducting detailed investigations of various AI models, ranging from basic machine learning algorithms to sophisticated deep learning models like convolutional neural networks (CNNs), recurrent neural networks (RNNs), generative adversarial networks (GANs), and transformer models.

Findings: Our analysis demonstrates that AI algorithms can significantly reduce human screening time, improve risk stratification, and provide more accurate predictions compared to conventional techniques [17], [18]. However, these benefits are accompanied by challenges, including data quality issues, algorithmic bias, understanding the "black box" nature of AI tools, regulatory constraints, and patient privacy and consent concerns.

Unique Contribution to Theory, Practice, and Policy: The article highlights AI's enormous potential to revolutionize clinical research. It recommends that successful implementation requires collaboration with the medical community to ensure ethical and responsible use, addressing the challenges of data quality, transparency, regulatory compliance, and patient rights.

Keywords: *Artificial Intelligence, Clinical Trials, Disease Modeling, Machine Learning, Precision Medicine, Risk Stratification, Personalized Medicine, Efficiency, Ethical Challenges, Privacy, Prediction.*

Introduction

Artificial Intelligence has the potential to revolutionize clinical trials and disease modeling, offering unprecedented opportunities to improve efficiency, accuracy, and personalization of healthcare. AI's ability to learn from vast datasets has become an area of such rapid innovation that it is now revolutionizing healthcare. This paper examines the application of Artificial Intelligence (AI) in clinical trials and disease modeling. Through a comprehensive literature review, we discovered that the integration of AI in clinical trials and disease modeling has been approached with considerable skepticism within the scientific community. However, the rapid advancements in high-performance computing, deep learning architectures, and the availability of large, diverse datasets have led to a surge of AI-driven research and applications in the medical field [1]. There have already been many areas in which the integration of AI has shown great promises, such as:

- **Streamlining Operations:** Hospital operations and management can be better optimized due to AI's ability to facilitate continuous monitoring and early interventions, creating a more impactful influence on both patients and clinicians.
- **Cost Saving and Increased Efficiency:** It helps reduce clinicians' time and effort by making certain analytical tasks much more efficient [2], which ultimately allows for better allocation of resources.
- **More Accurate Diagnoses and Treatment Plans:** With AI's capabilities in rapid analyses of medical images and data, it can provide clinicians with more accurate and faster diagnoses, allowing for more personalized and effective treatment plans [2].

Despite its significant potential, AI continues to face challenges that researchers and developers are actively working to address. Their goal is to maximize its positive impact while mitigating potential drawbacks particularly in stringent environments like **clinical trials** and disease modeling, where improper implementation could have **direct detrimental consequences**. This is why thorough research into AI's impact in these fields is essential.

Literature Review

A. AI in Clinical Trials

AI has the ability to sift through large datasets including health records, genomic profiles, and even media and can identify patients who meet trial eligibility criteria. This significantly reduces manual screening time while improving both recruitment efficiency and diversity. Additionally, specialized tools like natural language processing (NLP) can extract relevant patient information from clinical notes and other sources, accelerating the pre-screening process and ensuring accurate trial-candidate matching. This approach not only streamlines recruitment but also promotes fairness in trials, helping to ensure results are representative of the broader patient population [3]. The use of AI has also shown improvements in multiple ways [4], [5], [6]:

Journal of Technology and Systems
ISSN : 2788-6344 (Online)
Vol. 7, Issue No. 3, pp 12 – 22, 2025
www.carijournals.org

- **Trial Design and Monitoring**: Which helps for increasing trial success rates and minimizing failures [7].
- **Data Management and Analysis**: AI can also help manage diverse data generation and enhance the trial lifecycle. This includes interpreting data, feeding downstream systems, and automatically generating analysis reports—streamlining the process and reducing manual effort [3], [4].
- **Risk Stratification**: AI models could also help to tailor screening strategies and prioritize candidates based on their predicted benefits.

One notable case study comes from research on the TrialGPT framework, which leverages large language models for patient-to-trial matching. In this study, TrialGPT was evaluated on synthetic patient data with over 75,000 trial annotations. Its multi-step process included a retrieval module that achieved over 90% recall using less than 6% of the initial trial collection, and a matching module that reached an accuracy of 87.3%, a performance close to that of human experts [8]. Moreover, a user study revealed that the system reduced the screening time by about 42.6%, significantly speeding up the recruitment process [8]. More of the evaluation of this model is shown in Figure 1.



Figure 1: Shows manual evaluations of criterion-level predictions by GPT-4-based TrialGPT-Matching. And overall shows the greater enhancement that this model had in a clinical trial setting.

This case study demonstrates that integrating AI into clinical trial settings can substantially improve efficiency and accuracy in patient matching a critical factor for accelerating trial enrollment and enhancing overall outcomes. Beyond efficiency, these findings highlight AI's potential to enable personalized treatment approaches and contribute to more successful therapeutic results.

B. AI in Disease Modeling

Disease modeling is a critical tool for understanding disease progression, impact, and management. Many disease modeling techniques exist, with the most common ones listed in Figure 2. These approaches involve creating comprehensive models that cover the entire disease pathway—from preclinical stages to rest. Such models are used to guide resource allocation and assess interventions throughout a disease's progression [9]. Also, these models specifically helps to understand the disease dynamics, improving study designs, and evaluating treatment regimens [10].



Figure 2: Different types of Disease Modeling Techniques

AI and machine learning techniques are increasingly being applied to Disease Modeling to enhance the power and accuracy of these models. These techniques for data analysis and evidence-based practice have shown great promising in the modern era healthcare setting. Some of the main usecases of AI and Machine learning in Disease Modeling include:

- **Traditional ML Methods:** These include regression models, decision trees, and support vector machines. Traditional models rely on explicit feature selection and linear assumptions. In the field of disease, models can be used for predicting disease onset or progression based on risk factors and biomarkers [11].
- **Deep Learning in Predictive Modeling:** Particularly using convolutional neural networks (CNNs) and recurrent neural networks (RNNs), can automatically extract features from complex, high-dimensional data (most commonly image data).

Journal of Technology and Systems
ISSN : 2788-6344 (Online)
Vol. 7, Issue No. 3, pp 12 – 22, 2025
www.carijournals.org

- **Neural Network Applications:** Neural networks, including generative adversarial networks (GANs) and transformer-based models, have been applied to simulate disease progression and predict outcomes in various clinical contexts.

These AI-powered disease modeling processes have shown great promise in aiding clinical decision making, optimizing treatment regimes, and accelerating drug discovery, especially for rare diseases and other complex medical conditions.

For instance, there was a notable case study involved with the application of deep learning for rare disease detection. In one study, a generative adversarial network (GAN) was used to model disease progression for a rare condition by augmenting a small dataset of longitudinal medical claims [11]. This AI model outperformed traditional regression methods, achieving a PR-AUC of 0.56—demonstrating improved precision and recall in identifying patients with the disease [11]. This study illustrated that even when data are limited, advanced AI methods can enhance predictive accuracy and support earlier intervention [12]. The findings in Table 1 It showed the model performance of many different AI and Machine Learning models, and how it performed better than conventional methods in rare disease prediction [11].

Disease	Methods	Data Type	Sample Size	Model Performance	References
Adrenocortical carcinoma	clustering, RF DT	mRNA expression data differentially expressed proteins	79 117	ACC: 96%	[72] [73]
Alkaptonuria	XGBoost, k-NN custering	genetic, biochemical, histopathological, clinical, therapeutic resources, and QoL scores	129 112	RAE: 0.25, R2: 0.94	[75] [76]
Amyotrophic lateral sclerosis	RF, SVM	metabolomics data	38 (treated), 36 (placebo)	TPR: 71.4%, TNR: 71.4%, PPV: 71.4%, NPV: 70.0%	[77]
	LASSO, RF	a subset of the PRO-ACT dataset (survival and clinical data)	6565	C-index: 0.7355	[78]
	RF, XGBoost, BM, DT	a subset of the PRO-ACT dataset	3772	ACC: 71–84.7%	[79]
	GBoost, SVM	speech acoustic and articulatory data	1832	R2: 0.712, RMSE: 37.562	[80]
	ANN	Clinical and MRI data	135	ACC: 84.4%.	[81]
Huntington disease	ANN, FLS SVM, EL	finger-tapping tests data Neuroimaging data	3032 19 (preHD), 21(Controls)	R2: 0.98, MSE: 0.08 F1: 74%	[82] [83]
Cerebral arteriovenous malformation	ANN, SVM, Log Reg	clinical and imaging data	199	ACC: 97.5%	[84]
Progressive supranuclear palsy	LASSO, Lin Reg	Imaging data	53	R2: 0.892	[85]
Behavioral variant of frontotemporal dementia	SVM	clinical and structural MRI data	73	ACC: 72–82%, TPR: 67–79%, TNR; 77–88%, AUC: 0.80–0.9	[86]
Diamond-Blackfan anemia	SVM	structural data of missense mutation	29 (positive samples), 30 (negative samples)	ACC: 95%, TPR: 90%, TNR; 98% F1: 94%	[87]
Duchenne muscular dystrophy	EL	inertial sensor (accelerometer) data	7	RMSE: 0.017	[88]
Primary sclerosing cholangitis	GBoost	clinical and laboratory data	509	C-index: 0.90	[89]
Juvenile-onset systemic lupus erythematosus	RF	Immunophenotyping data	67 (jSLE), 39 (Controls)	ACC: 86·8%	[90]
Pediatric myocarditis	RF RF, Log Reg	Diagnoses/procedures data from the Kids' Inpatient Database	7241 4144	CI: 95% TPR: 89.9% TNR: 85.8%, ACC: 87.9%	[91] [92]

These advancements in AI-powered disease modeling not only improve diagnosis and treatment for more common conditions, but also have major implications for rare diseases, which often lack large datasets to train traditional statistical models. By extracting deep insights from complex, heterogeneous data, AI has great potential to accelerate progress in the understanding and management of rare diseases [11] [13].

C. Current Gaps and Limitations

Artificial intelligence-driven disease models and clinical trials hold enormous potential to revolutionize medicine by enabling earlier diagnosis, optimized treatment planning, and personalized patient care. These models range from classical machine learning techniques—such as logistic regression and decision trees—to advanced deep learning architectures, including CNNs for image processing, RNNs for sequence data, GANs for synthetic data generation, and transformer-based models for natural language tasks. Despite these innovations, significant challenges must be overcome to ensure their safe and effective implementation. Failure to address these issues risks misdiagnosis, inefficient trial designs, and the perpetuation of healthcare disparities.

One of the primary issues in current used of AI and Machine Learning must deal with incomplete or unrepresented data, poor data or datasets lacking diversity can lead to biased data that do not generalize well across different patient populations. Also, Interpretability and Explainability, are a huge issue. “Black Box” is a common phrase in the modern area of AI and Machine Learning. The main ideas with this are “models that provide outputs without offering insight into their internal workings” [14], Figure 3. Ultimately, for AI to be trusted and accepted in a clinical setting, the results must be clearly interpretable and traceable. Moreover, when these two issues and the interpretability combine, the issues that can arise specifically in a field like healthcare can be detrimental as it could cause direct harm if not properly handled.



Figure 3: This is the regular flow in which AI and Machine Learning models works, one of the main ideas here is the idea of Hidden Layers, due the way that these models are structured, there is no true way for us to understand how they arrive at their outputs, and this is where the term “Black Box” comes from.

In summary, the use of AI-based approaches in clinical trials and disease modeling is a rapidly evolving field with immense potential, but it is not without its limitations and challenges. Addressing these challenges is critical to fully realizing the benefits of AI in clinical trials and disease modeling, ensuring that advancements are not only effective but also ethical, transparent, and equitable.

Methodology

This paper provides a comprehensive literature review and case study on the application of artificial intelligence in clinical trials and disease modeling. Rigorous data collection and meticulous analysis were essential to ensure the validity and reliability of the findings.

1. **Research Approach:** This study follows a qualitative research approach, focusing on gathering and synthesizing relevant literature on the topic of AI in clinical trials and disease modeling.

2. **Data Collection Strategy:** The data for this paper was gained through the comprehensive research, there have been many different case studies in which organizations have measure performance of different AI and Machine Learning models in the field of healthcare. By using articles and studies conducted by well know organizations and research institutes, a consolidated dataset is formed on the performance of AI in clinical trials and disease modeling.

3. **Analysis Framework:** The analysis for this paper focused on AI application in clinal trials and disease modeling settings. By looking through the vast data on the performance of AI models, key insights are drawn on the advancements, limitations, and future directions in this field.

Results

A. Pros

Across the reviewed studies, AI models (e.g., deep neural networks, ensemble algorithms) demonstrated high accuracy, sensitivity, and specificity. For instance, the TrialGPT framework for patient-to-trial matching achieved an 87.3% accuracy with a recall rate exceeding 90% in preliminary evaluations, reducing screening times by over 40% [8]. Another study leveraged neural networks to model disease progression in Huntington's disease, achieving a Pearson correlation of 0.81 between predicted and true clinical scores [15]. These findings showcase the ability of AI to enhance the efficiency and precision of clinical trial recruitment and disease forecasting.

In disease modeling, advanced methods such as generative adversarial networks (GANs) used for rare disease detection reported a PR-AUC of 0.56, outperforming conventional regression models in precision and recall metrics [12], [11]. These results highlight the potential of AI to tackle the challenges of complex, high-dimensional data that often characterize medical and clinical settings. The findings from this comprehensive review and case study on AI in clinical trials and disease modeling present a compelling narrative of the transformative potential of these technologies [16].

- There is a noticeable trend towards integrating multi-model data sources to create comprehensive disease models.
- Adaptive trials designs that incorporate real-time AI analytics are emerging as promising methodologies to improve trial success rates while still minimizing failures.

B. Cons

However, the reviewed literature also identified key limitations and obstacles to the widespread adoption of AI in these domains: Ethical issues, data quality and bias, regulatory hurdles, and the interpretability of AI models remain significant barriers that must be addressed through multidisciplinary collaboration and responsible development, Figure 5.

- **Privacy and Ethical Considerations:** Firstly, patient privacy and consent are critical ethical concerns when deploying AI systems that utilize sensitive health data. Potential

Journal of Technology and Systems
ISSN : 2788-6344 (Online)
Vol. 7, Issue No. 3, pp 12 – 22, 2025
www.carijournals.org

algorithmic biases stemming from non-representative datasets must also be carefully mitigated.

- **Data Diversity issues:** Secondly, the heterogeneity, quality, and availability of data remain major challenges. Standardization of data formats, integration of diverse data sources, and strategies to handle missing data are active areas of research and development.



Figure 5: Overall summaries the pros and cons of using AI in clinical trials and disease modeling based on the key insights from the literature review.

Conclusion

A. Summary

Clinical trial processes have become more efficient and accurate thanks to AI which especially boosts patient recruitment, trial design and risk stratification. Research into rare diseases has gained momentum through the application of AI-powered disease models which have demonstrated potential to improve our grasp of disease progression and treatment outcomes. Deep learning and neural network approaches in disease modeling show better performance than traditional statistical methods by delivering profound insights into disease progression and supporting earlier personalized interventions. However, the successful adoption of AI in healthcare continues to face significant challenges around data quality, ethical considerations, and regulatory approval.

B. Looking into the Future

AI will continue to play a pivotal role in the future of clinical research and healthcare. As newer advancements in the field such as transfer learning, federated learning, and multi-task architectures emerge overcome some of the current limitations, the integration of AI into routine clinical practice will accelerate. Future action may focus on guidelines like these [17], [18], [15]:

- Conduct larger, multi-center, and prospective studies to validate AI models externally.
- Focus on enhancing model interpretability and developing standardized reporting frameworks to ensure transparency and reproducibility.
- Expand data sources, particularly for rare diseases, by integrating real-world and data to improve training datasets [19].

AI integration into clinical trials and disease modeling presents transformative opportunities for healthcare because it allows for personalized treatment strategies while lowering operational expenses and enhancing patient outcomes. When these technologies reach maturity they will transform both clinical research methods and healthcare delivery while speeding up processes and creating more personalized patient care.

References

[1] S. M. Varnosfaderani and M. Forouzanfar, “The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century,” Mar. 29, 2024, Multidisciplinary Digital Publishing Institute. doi: 10.3390/bioengineering11040337.

[2] S. A. Alowais et al., “Revolutionizing healthcare: the role of artificial intelligence in clinical practice,” BMC Medical Education, vol. 23, no. 1. BioMed Central, Sep. 22, 2023. doi: 10.1186/s12909-023-04698-z.

[3] I. N. Weerarathna, A. R. Kamble, and A. Luharia, "Artificial Intelligence Applications for Biomedical Cancer Research: A Review," Cureus. Cureus, Inc., Nov. 05, 2023. doi: 10.7759/cureus.48307.

[4] S. Harrer, P. Shah, B. Antony, and J. Hu, "Artificial Intelligence for Clinical Trial Design," Trends in Pharmacological Sciences, vol. 40, no. 8. Elsevier BV, p. 577, Jul. 17, 2019. doi: 10.1016/j.tips.2019.05.005.

[5] X. Lu, C. Ming-an, Z. Lu, X. Shi, and L. Liang, "Artificial intelligence tools for optimising recruitment and retention in clinical trials: a scoping review protocol," BMJ Open, vol. 14, no. 3. BMJ, Mar. 01, 2024. doi: 10.1136/bmjopen-2023-080032.

[6] A. Cundari, "How Artificial Intelligence (AI) is Revolutionizing Clinical Trials." Sep. 2024. Accessed: Mar. 15, 2025. [Online]. Available: https://www.linical.com/articles-research/how-ai-is-revolutionizing-clinical-trials

[7] X. Lu, Y. Chen, L. Liang, G. Hu, Z. Zhong, and Z. Jiang, "Artificial intelligence for optimizing recruitment and retention in clinical trials: a scoping review," Journal of the American Medical Informatics Association. Oxford University Press, Sep. 11, 2024. doi: 10.1093/jamia/ocae243.

[8] Q. Jin et al., "Matching Patients to Clinical Trials with Large Language Models," Jan. 01, 2023, Cornell University. doi: 10.48550/arxiv.2307.15051.

[9] P. Tappenden, J. Chilcott, A. Brennan, H. Squires, R. Glynne-Jones, and J. Tappenden, "Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model," Value in Health, vol. 16, no. 4. Elsevier BV, p. 542, May 16, 2013. doi: 10.1016/j.jval.2013.02.012.

[10] S. F. Cook and R. R. Bies, "Disease Progression Modeling: Key Concepts and Recent Developments," Aug. 14, 2016, Springer Science+Business Media. doi: 10.1007/s40495-016-0066-x.

[11] A. Visibelli, B. Roncaglia, O. Spiga, and A. Santucci, "The Impact of Artificial Intelligence in the Odyssey of Rare Diseases," Biomedicines, vol. 11, no. 3. Multidisciplinary Digital Publishing Institute, p. 887, Mar. 13, 2023. doi: 10.3390/biomedicines11030887.

[12] P. Dey, C. Ogwo, and M. Téllez, "Comparison of traditional regression modeling vs. AI modeling for the prediction of dental caries: a secondary data analysis," May 24, 2024, Frontiers Media. doi: 10.3389/froh.2024.1322733.

[13] M. Wojtara, E. Rana, T. Rahman, P. Khanna, and H. Singh, "Artificial intelligence in rare disease diagnosis and treatment," Clinical and Translational Science, vol. 16, no. 11. Wiley, p. 2106, Aug. 30, 2023. doi: 10.1111/cts.13619.

[14] M. A. Al-antari, "Artificial Intelligence for Medical Diagnostics—Existing and Future AI Technology!," Diagnostics, vol. 13, no. 4. Multidisciplinary Digital Publishing Institute, p. 688, Feb. 12, 2023. doi: 10.3390/diagnostics13040688.

[15] C. Kelly, A. Karthikesalingam, M. Suleyman, G. S. Corrado, and D. King, “Key challenges for delivering clinical impact with artificial intelligence,” Oct. 29, 2019, BioMed Central. doi: 10.1186/s12916-019-1426-2.

[16] B. Bhinder, C. Gilvary, N. S. Madhukar, and O. Elemento, “Artificial Intelligence in Cancer Research and Precision Medicine,” Cancer Discovery, vol. 11, no. 4. American Association for Cancer Research, p. 900, Apr. 01, 2021. doi: 10.1158/2159-8290.cd-21-0090.

[17] A. Shuaib, “Transforming Healthcare with AI: Promises, Pitfalls, and Pathways Forward,” May 01, 2024, Dove Medical Press. doi: 10.2147/ijgm.s449598.

[18] C. Giordano, M. Brennan, B. Mohamed, P. Rashidi, F. Modave, and P. Tighe, “Accessing Artificial Intelligence for Clinical Decision-Making,” Frontiers in Digital Health, vol. 3. Frontiers Media, Jun. 25, 2021. doi: 10.3389/fdgth.2021.645232.

[19] F. Mirakhori and S. K. Niazi, “Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective,” Oct. 31, 2024. doi: 10.20944/preprints202410.2510.v1.

©2025 by the Authors. This Article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)